Received Oct 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19-2 | COVID19 (COVID19 (MODERNA BIVALENT)) | MODERNA | UNK | — | — |
contracted Covid-19 "in the last 2-3 years; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (contracted Covid-19 "in the last 2-3 years) in a 64-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis. No Medical History information was reported. In 2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. In 2023, the patient experienced COVID-19 (contracted Covid-19 "in the last 2-3 years). At the time of the report, COVID-19 (contracted Covid-19 "in the last 2-3 years) outcome was unknown. No concomitant medication was reported. Patient received the vaccine in approximates Fall of 2022. Patient had received all Moderna Covid vaccines and contracted Covid-19 in the last 2-3 years approximately sometime in 2023. No treatment information was provided. This case was linked to US-MODERNATX, INC.-MOD-2025-789717 (E2B Linked Report).; Sender's Comments: US-MODERNATX, INC.-MOD-2025-789717:female patient case